Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Recro Pharma, Inc.
  6. Summary
    REPH   US75629F1093

RECRO PHARMA, INC.

(REPH)
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
1.65(c) 1.63(c) 1.55(c) 1.56(c) 1.53(c) Last
73 631 90 986 245 111 160 141 122 023 Volume
-1.79% -1.21% -4.91% +0.65% -1.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 74,5 M - -
Net income 2021 -12,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,04x
Yield 2021 -
Sales 2022 91,4 M - -
Net income 2022 -16,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,34x
Yield 2022 -
Capitalization 71,9 M 71,9 M -
Capi. / Sales 2021 0,97x
Capi. / Sales 2022 0,79x
Nbr of Employees -
Free-Float 97,2%
More Financials
Company
Recro Pharma, Inc. is a contract development and manufacturing organization (CDMO). The Company is engaged in solving formulation and manufacturing challenges for companies developing oral solid dose drug products. It also focuses on developing sterile injectables oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. It operates in one segment. It... 
Sector
Pharmaceuticals
Calendar
02/24Earnings Release
More about the company
Ratings of Recro Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about RECRO PHARMA, INC.
01/26Recro Pharma Receives $1.5 Million Formulation Development, Manufacturing Contract from..
MT
01/26Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Supp..
GL
01/24Recro Pharma, Inc. Announces Resignation of Gerri A. Henwood from Board of Directors
CI
01/19Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
GL
01/19Recro Pharma, Inc Appoints Eduardo Uribe as the Head of Quality for Recro San Diego
CI
01/14RECRO PHARMA : Unaudited Pro Forma Combined Statements of Operations Nine Months Ended Sep..
PU
01/06Recro Reports Inducement Grants For New Staff
AQ
01/03Recro to Present at H.C. Wainwright BioConnect 2022 Conference
GL
2021Recro to Present at Stephens Annual Investment Conference
AQ
2021Recro Reports Third Quarter 2021 Financial Results - Form 8-K
PU
2021Earnings Flash (REPH) RECRO PHARMA Posts Q3 Revenue $18.2M, vs. Street Est of $18.1M
MT
2021Recro Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
2021Recro Pharma, Inc. Provides Earnings Guidance for the Full Year 2021
CI
2021Recro Reports Third Quarter 2021 Financial Results
AQ
2021Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021
GL
More news
News in other languages on RECRO PHARMA, INC.
01/24Recro Pharma, Inc. annonce la démission de Gerri A. Henwood de son conseil d'administra..
01/19Recro Pharma, Inc. nomme Eduardo Uribe au poste de responsable de la qualité pour Recro..
2021Earnings Flash (REPH) RECRO PHARMA affiche un chiffre d'affaires de 18,2 millions de do..
2021Recro Pharma, Inc. fournit des prévisions de résultats pour l'ensemble de l'année 2021
2021Recro Pharma signe une lettre d'intention en vue d'acquérir une organisation de dévelop..
More news
Analyst Recommendations on RECRO PHARMA, INC.
More recommendations
Chart RECRO PHARMA, INC.
Duration : Period :
Recro Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECRO PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
J. David Enloe President, Chief Executive Officer & Director
Ryan D. Lake Chief Financial Officer & Treasurer
Wayne B. Weisman Chairman
Richard Sidwell Chief Scientific Officer & Senior Vice President
David Smithwick Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
RECRO PHARMA, INC.-10.53%72
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642